Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXI-109 for Keloid Recurrence
NCT02079168Phase 2Completed
- Sponsor
- Phio Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of CTGF siRNA in keloid, sponsored by Phio Pharmaceuticals. Started Mar 2014; status: completed.
02
Drugs
CTGF siRNA
03
Conditions
keloid
Beyond the preview
Go deeper on NCT02079168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079168.